4.5 Review

Recent advances in CD8+T cell-based immune therapies for HIV cure

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

CD8+ T cells promote HIV latency by remodeling CD4+ T cell metabolism to enhance their survival , quiescence, and stemness

Simona Mutascio et al.

Summary: Using a primary cell-based in vitro latency model, this study demonstrates that CD8+ T cells can suppress HIV expression and promote latency by inducing specific changes in metabolic and signaling pathways that increase CD4+ T cell survival and stemness. This discovery of CD8-specific mechanisms involved in pro-latency activity may contribute to the development of strategies to eliminate the viral reservoir in individuals with HIV.

IMMUNITY (2023)

Article Multidisciplinary Sciences

HIV post-treatment controllers have distinct immunological and virological features

Behzad Etemad et al.

Summary: This study evaluated the mechanisms of HIV post-treatment control and found that post-treatment controllers (PTCs) had stable HIV reservoirs and better immunological profiles. These findings have implications for future studies aiming at achieving an HIV functional cure.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Biochemistry & Molecular Biology

Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses

Kevin B. Einkauf et al.

Summary: By studying the evolution of transcriptionally active and silent proviral genomes and epigenomes in individuals receiving antiretroviral therapy, we have found that transcriptionally active HIV-1 proviruses are dynamically evolving under host factors' selection pressure.
Article Immunology

Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy

Chris Y. Chiu et al.

Summary: Blocking immune checkpoint (IC) proteins, particularly in combination with antibodies to LAG-3, CTLA-4, or TIGIT, shows potential in enhancing the elimination of HIV-infected cells and improving the activation and survival of immune cells in people with HIV on antiretroviral therapy (ART).

JOURNAL OF IMMUNOLOGY (2022)

Article Biochemistry & Molecular Biology

Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

Jeffrey S. Miller et al.

Summary: N-803 is a safe and potential treatment for reducing virus reservoirs in people living with HIV by activating latent virus and enhancing immune cell function.

NATURE MEDICINE (2022)

Article Microbiology

CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection

Mary S. Pampusch et al.

Summary: Infusion of T cells expressing the SIV-specific chimeric antigen receptor (CAR) and the follicular homing receptor, CXCR5, into SIV-infected monkeys can successfully target and kill viral-RNA(+) cells in lymphoid follicles. This immunotherapy shows promise in reducing viral loads and follicular viral RNA levels, potentially leading to long-term remission of HIV.

PLOS PATHOGENS (2022)

Review Medicine, General & Internal

Immune checkpoint blockade in HIV

Celine Gubser et al.

Summary: Antiretroviral therapy (ART) has greatly improved the life expectancy of people with HIV, but chronic HIV infection leads to immune exhaustion and persistent immune dysfunction. Recent evidence suggests that immune checkpoint blockade may contribute to HIV cure or remission by reversing HIV-latency and promoting recovery of HIV-specific T-cells.

EBIOMEDICINE (2022)

Article Multidisciplinary Sciences

Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers

Luis M. Molinos-Albert et al.

Summary: This study characterized the humoral immune response to HIV-1 in post-treatment controllers and found that they can be divided into two distinct groups based on viral behavior and immune signatures. Virally-exposed post-treatment controllers displayed stronger immune responses, which may contribute to their ability to control infection.

NATURE COMMUNICATIONS (2022)

Article Cell Biology

Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer

Marine Baron et al.

Summary: The study suggests that ICP blockade could be a potential therapeutic strategy for HIV cure. Anti-PD-1 therapy showed a decrease in HIV-DNA, but no significant increase in HIV-specific immunity. It was observed that there was an early increase in CTLA-4+ CD4+ T cells and a greater increase in CTLA-4+ and TIM-3+ CD8+ T cells in patients without HIV-DNA reduction.
Article Immunology

Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

John D. Ventura et al.

Summary: This study investigated the therapeutic efficacy of an Ad26/MVA vaccine with vesatolimod in ART-suppressed, SIVmac251-infected rhesus macaques. The vaccine led to robust immune responses and virologic control was observed after discontinuation of ART. SIV-specific cellular immune responses correlated with virologic control.

NPJ VACCINES (2022)

Article Immunology

Myeloid cell tropism enables MHC-E-restricted CD8+ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine

Scott G. Hansen et al.

Summary: This study demonstrates the crucial role of MHC-E-restricted CD8(+) T cell responses in the efficacy of the RhCMV/SIV vaccine. Selective inhibition of RhCMV infection in different cell types using host microRNA-mediated vector tropism restriction controlled the CD8(+) T cell responses.

SCIENCE IMMUNOLOGY (2022)

Review Veterinary Sciences

The role of latency reversal in HIV cure strategies

Kiho Tanaka et al.

Summary: Although multiple latency reversal agents have shown activity in vitro, clinical trials have not demonstrated significant reduction in latently infected cells. New insights into the biology of HIV latency are being reviewed and novel approaches to enhance the efficacy of latency reversal agents are being discussed.

JOURNAL OF MEDICAL PRIMATOLOGY (2022)

Article Medicine, General & Internal

Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells

Hiroshi Takata et al.

Summary: ART initiation in acute HIV infection preserves functional HIV-specific CD8(+) T cells, albeit at numbers too low to control viral rebound post-ART. HIV remission strategies may need to boost HIV-specific CD8(+) T cell numbers and induce stem cell-like properties to reverse the residual dysfunction persisting on ART in people treated after acute infection prior to ART release.

EBIOMEDICINE (2022)

Article Medicine, Research & Experimental

Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control

Federico Perdomo-Celis et al.

Summary: Virus-specific CD8(+) T cells play a central role in HIV-1 control and can be reprogrammed to enhance their antiviral potential through targeting specific signaling pathways.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Review Oncology

Immune Checkpoint Inhibitors in Cancer Therapy

Yavar Shiravand et al.

Summary: The discovery of immune checkpoint proteins has revolutionized cancer immunotherapy, leading to the successful utilization of targeted monoclonal antibodies in various cancer patients. However, not all patients respond favorably to these drugs, emphasizing the need for biomarkers to predict treatment responses.

CURRENT ONCOLOGY (2022)

Article Immunology

Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia

Yoshiaki Nishimura et al.

Summary: The study found that combination bNAb immunotherapy initiated on day 3 post-infection maintained durable CD8(+) T cell-mediated suppression of SHIVAD8 viremia and CD4(+) T cell levels in most of the treated monkeys during nearly 6 years of observation, with CD8(+) T cell immunity being the principal correlate of virus control. Treatment interventions beginning on week 2 post-infection also conferred controller status to some monkeys, but the time to suppression of plasma viremia was significantly delayed compared to early intervention on day 3.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Article Immunology

MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects

Vivek Verma et al.

Summary: MEKi inhibition can induce CD8(+) T cell reprogramming into cells with stem cell-like memory characteristics, which exhibit stronger antitumor responses.

NATURE IMMUNOLOGY (2021)

Article Cell Biology

Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption

Marcos V. P. Gondim et al.

Summary: Type 1 interferons (IFN-I) have potent antiviral effects against HIV-1, but their resistance in later stages of infection remains high. A study of 500 clonally derived HIV-1 isolates found that resistance to IFN-I decreases in the first year after infection, increases with CD4(+) T cell loss, and is highest during viral rebound after treatment interruption. This dynamic interplay between host innate responses and the evolving HIV-1 quasispecies affects the control of HIV-1 by IFN-I.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Review Immunology

Multi-stakeholder consensus on a target product profile for an HIV cure

Sharon R. Lewin et al.

Summary: Developing a cure for HIV is a global priority. Three distinct therapeutic modalities for a target product profile were identified. There is consensus regarding the criteria for the optimum target product profile, with the understanding that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy. Successful cure of a reasonable fraction of adults would be sufficient to advance to clinical trials.

LANCET HIV (2021)

Article Immunology

Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection

Analia Uruena et al.

Summary: This study describes a unique case of an HIV-positive woman with prior AIDS who has not experienced viral rebound for over 12 years since discontinuing antiretroviral therapy. No HIV-specific antibodies were detected in her serum, and her viral load is extremely low with persistent HIV-specific T-cell responses.

OPEN FORUM INFECTIOUS DISEASES (2021)

Article Medicine, Research & Experimental

TCF-1 regulates HIV-specific CD8+ T cell expansion capacity

Rachel L. Rutishauser et al.

Summary: The transcription factor TCF-1 plays a crucial role in regulating the memory properties and expansion capacity of virus-specific CD8(+) T cells, which are important for controlling HIV infection. Increasing TCF-1 levels may enhance the secondary expansion capacity of HIV-specific CD8(+) T cells.

JCI INSIGHT (2021)

Article Biochemistry & Molecular Biology

Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy

Jana Blazkova et al.

Summary: The control of viral rebound after cessation of medication may be regulated by CD8 T cell activity or neutralizing antibodies, with different individuals exhibiting distinct mechanisms. Continuous monitoring of undisclosed use of medication and superinfection is crucial for controlling plasma viral rebound.

NATURE MEDICINE (2021)

Review Biochemistry & Molecular Biology

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

Steven G. Deeks et al.

Summary: Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. Various methods including immune activators, neutralizing antibodies, therapeutic vaccines, and gene editing tools have shown promise in curing HIV in nonhuman primate models, with optimism for human clinical trials. Future HIV cure strategies may focus on in vivo delivery of gene-editing tools to target the virus, boost immunity, or protect cells from infection.

NATURE MEDICINE (2021)

Article Virology

CD8 Lymphocyte Depletion Enhances the Latency Reversal Activity of the SMAC Mimetic AZD5582 in ART-Suppressed Simian Immunodeficiency Virus-Infected Rhesus Macaques

Maud Mavigner et al.

Summary: The study demonstrated that inducing latency reversal using the SMAC mimetic/IAP inhibitor AZD5582, in combination with CD8 alpha cell depletion, can enhance viral latency reversal in SIV-infected rhesus macaques. All six animals treated with the combined therapy showed increased on-ART viremia, indicating a potential role of CD8(+) T cells in maintaining and inhibiting latency reversal during HIV/SIV infection.

JOURNAL OF VIROLOGY (2021)

Article Immunology

The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy

Jillian S. Y. Lau et al.

Summary: In individuals with HIV on antiretroviral therapy and malignancy, immune checkpoint blockade therapy was found to activate latent HIV and enhance HIV-specific T cell function, but with significant variation among individuals.
Letter Immunology

Suspected Immune-Related Adverse Events With an Anti-PD-1 Inhibitor in Otherwise Healthy People With HIV

Cynthia L. Gay et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2021)

Article Medicine, Research & Experimental

CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification

Afam A. Okoye et al.

Summary: The study found that CD8+ T cell depletion did not significantly affect the control of SIV reactivation during ART, but after ART cessation, rhesus macaques with CD8+ T cell depletion showed a significant increase in post-ART plasma viremia.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Review Immunology

Epigenetic Mechanisms of HIV-1 Persistence

Roxane Verdikt et al.

Summary: The article emphasizes the complexity and dynamics of the heterochromatinization of HIV-1 in different reservoirs, while discussing the importance of further understanding HIV-1 gene regulation for the rational design of novel HIV-1 cure strategies.

VACCINES (2021)

Article Immunology

Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

Yugang Guo et al.

Summary: The study demonstrates that a half-life-extended IL-10-Fc fusion protein can enhance the function of terminally exhausted CD8(+) tumor-infiltrating lymphocytes by promoting oxidative phosphorylation, leading to improved response to cancer immunotherapy.

NATURE IMMUNOLOGY (2021)

Article Cell Biology

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

Devi SenGupta et al.

Summary: TLR7 agonist vesatolimod, when combined with ART, showed potential to delay viral rebound in HIV-1-infected controllers by reducing intact proviral DNA levels at the end of treatment. Further larger clinical studies are needed to evaluate the efficacy of vesatolimod-based combination therapies for long-term control of HIV infection.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Immunology

PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue

Sheikh Abdul Rahman et al.

Summary: Therapeutic vaccination with a CD40L plus TLR7 adjuvant induced robust SIV-specific CD4(+) and CD8(+) T cell responses under ART, while PD-1 blockade further enhanced CD8(+) T cell function and localization in B cell follicles, reducing viral reservoirs and improving survival. These findings suggest potential implications for the development of curative HIV strategies.

SCIENCE IMMUNOLOGY (2021)

Article Medicine, Research & Experimental

Broadly neutralizing antibody derived CAR T cells reduce viral reservoir in individuals infected with HIV-1

Bingfeng Liu et al.

Summary: This study investigated the safety and antiviral activity of bNAb-derived CAR T cell therapy in individuals infected with HIV-1 undergoing analytical interruption of antiretroviral therapy. The therapy was found to be safe and effective, reducing viral reservoir, but rebound was due to viral escape mutations.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Review Medicine, Research & Experimental

How elite controllers and posttreatment controllers inform our search for an HIV-1 cure

Jonathan Z. Li et al.

Summary: A small percentage of HIV-1 patients, known as elite controllers (ECs) or posttreatment controllers (PTCs), can control viral replication without antiretroviral therapy. Although these patients may serve as a model for a functional cure for HIV-1, the mechanisms responsible for viral control remain unclear. Research on controllers provides important insights for HIV cure research.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Article Biotechnology & Applied Microbiology

T cell-based strategies for HIV-1 vaccines

Bette Korber et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)

Article Multidisciplinary Sciences

Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells

Julia Bergild McBrien et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity

Julia Niessl et al.

NATURE MEDICINE (2020)

Review Microbiology

The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies

Lillian B. Cohn et al.

CELL HOST & MICROBE (2020)

Review Immunology

Advances in Developing CAR T-Cell Therapy for HIV Cure

Jinxin Qi et al.

FRONTIERS IN IMMUNOLOGY (2020)

Article Multidisciplinary Sciences

Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1

Lynn N. Bertagnolli et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Review Immunology

CD8+ T cells in HIV control, cure and prevention

David R. Collins et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Article Immunology

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

Laura M. McLane et al.

Annual Review of Immunology (2019)

Review Oncology

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Filipe Martins et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Article Multidisciplinary Sciences

VACCINOLOGY Structural topology defines protective CD8+ T cell epitopes in the HIV proteome

Gaurav D. Gaiha et al.

SCIENCE (2019)

Article Multidisciplinary Sciences

CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques

Jin Fan et al.

NATURE COMMUNICATIONS (2019)

Review Immunology

CD8+ T-Cell Response to HIV Infection in the Era of Antiretroviral Therapy

Federico Perdomo-Celis et al.

FRONTIERS IN IMMUNOLOGY (2019)

Article Biochemistry & Molecular Biology

Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform

Eytan Herzig et al.

Review Multidisciplinary Sciences

Why and where an HIV cure is needed and how it might be achieved

Thumbi Ndung'u et al.

NATURE (2019)

Article Medicine, Research & Experimental

The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells

Alice Gutjahr et al.

JCI INSIGHT (2019)

Review Microbiology

Getting the Kill into Shock and Kill: Strategies to Eliminate Latent HIV

Youry Kim et al.

CELL HOST & MICROBE (2018)

Article Medicine, Research & Experimental

Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells

Szu-Han Huang et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Article Medicine, Research & Experimental

HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers

Radwa Sharaf et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Article Multidisciplinary Sciences

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

Erica N. Borducchi et al.

NATURE (2018)

Article Medicine, Research & Experimental

Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity

Karolina Pilipow et al.

JCI INSIGHT (2018)

Review Immunology

CAR T cells for infection, autoimmunity and allotransplantation

Colby R. Maldini et al.

NATURE REVIEWS IMMUNOLOGY (2018)

Article Multidisciplinary Sciences

Early antibody therapy can induce long-lasting immunity to SHIV

Yoshiaki Nishimura et al.

NATURE (2017)

Article Biochemistry & Molecular Biology

Defining total-body AIDS-virus burden with implications for curative strategies

Jacob D. Estes et al.

NATURE MEDICINE (2017)

Review Biochemistry & Molecular Biology

Impairment of the type I interferon response by HIV-1: Potential targets for HIV eradication

Teslin S. Sandstrom et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2017)

Review Immunology

Interleukin 17 is a chief orchestrator of immunity

Marc Veldhoen

NATURE IMMUNOLOGY (2017)

Review Medicine, Research & Experimental

The host STING pathway at the interface of cancer and immunity

Leticia Corrales et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Article Biochemistry & Molecular Biology

Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites

Farokh Dotiwala et al.

NATURE MEDICINE (2016)

Article Multidisciplinary Sciences

Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E

Scott G. Hansen et al.

SCIENCE (2016)

Review Immunology

Triggering Intracellular Receotors for Vaccine Acjuvantation

Alice Gutjahr et al.

TRENDS IN IMMUNOLOGY (2016)

Review Biochemistry & Molecular Biology

HIV-1 Reservoirs During Suppressive Therapy

Kirston Barton et al.

TRENDS IN MICROBIOLOGY (2016)

Review Immunology

Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change

Giuseppe Pantaleo et al.

CURRENT OPINION IN HIV AND AIDS (2016)

Review Immunology

Designing optimal HIV-vaccine T-cell responses

Hendrik Streeck

CURRENT OPINION IN HIV AND AIDS (2016)

Review Immunology

Immune activation during acute HIV infection and the impact of early antiretroviral therapy

Shelly J. Krebs et al.

CURRENT OPINION IN HIV AND AIDS (2016)

Article Biochemistry & Molecular Biology

B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers

Yoshinori Fukazawa et al.

NATURE MEDICINE (2015)

Review Biochemistry & Molecular Biology

Elite control of HIV: is this the right model for a functional cure?

Leslie R. Cockerham et al.

TRENDS IN MICROBIOLOGY (2015)

Article Endocrinology & Metabolism

Dyslipidemia and Cardiovascular Risk in Human Immunodeficiency Virus Infection

Theodoros Kelesidis et al.

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2014)

Article Biotechnology & Applied Microbiology

Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1

Nicola Borthwick et al.

MOLECULAR THERAPY (2014)

Article Multidisciplinary Sciences

Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys

James B. Whitney et al.

NATURE (2014)

Review Immunology

HIV-associated chronic immune activation

Mirko Paiardini et al.

IMMUNOLOGICAL REVIEWS (2013)

Review Immunology

HIV controllers: a genetically determined or inducible phenotype?

Asier Saez-Cirion et al.

IMMUNOLOGICAL REVIEWS (2013)

Article Multidisciplinary Sciences

Immune clearance of highly pathogenic SIV infection

Scott G. Hansen et al.

NATURE (2013)

Article Multidisciplinary Sciences

Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms

Scott G. Hansen et al.

SCIENCE (2013)

Review Medicine, Research & Experimental

New Paradigms for HIV/AIDS Vaccine Development

Louis J. Picker et al.

ANNUAL REVIEW OF MEDICINE, VOL 63 (2012)

Article Immunology

A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection

Felipe Garcia et al.

JOURNAL OF INFECTIOUS DISEASES (2011)

Article Multidisciplinary Sciences

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

Scott G. Hansen et al.

NATURE (2011)

Article Multidisciplinary Sciences

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Florencia Pereyra et al.

SCIENCE (2010)

Article Immunology

Novel Human Interleukin-15 Agonists

Xiaoyun Zhu et al.

JOURNAL OF IMMUNOLOGY (2009)

Article Multidisciplinary Sciences

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

Jinyan Liu et al.

NATURE (2009)

Article Medicine, General & Internal

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

M. Juliana McElrath et al.

LANCET (2008)

Review Medicine, General & Internal

Medical progress: The challenge of HIV-1 subtype diversity

Barbara S. Taylor et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Multidisciplinary Sciences

A whole-genome association study of major determinants for host control of HIV-1

Jacques Fellay et al.

SCIENCE (2007)

Article Multidisciplinary Sciences

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype

Asier Saez-Cirion et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

Article Biochemistry & Molecular Biology

NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation

SA Williams et al.

EMBO JOURNAL (2006)

Article Biochemistry & Molecular Biology

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

JD Siliciano et al.

NATURE MEDICINE (2003)

Article Multidisciplinary Sciences

Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity

S Oh et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)

Article Biochemistry & Molecular Biology

HIV-1 Nef downregulates MHC-I by a PACS-1-and PI3K-regulated ARF6 endocytic pathway

AD Blagoveshchenskaya et al.

Article Multidisciplinary Sciences

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

SA Migueles et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)